Access
To read this story in full you will need to login or make a payment (see right).
News
Nature 447, 513 (31 May 2007) | doi:10.1038/447513a; Published online 30 May 2007
Open Innovation Challenges
-
Efficient Chromosome Doubling: Plant Cell Division
The Seeker is looking for an efficient chromosome doubling method in plants and in particular, metho...
-
Protect Enzyme from In Planta Degradation
A proposal for stable expression of an enzyme in corn seed is desired.
- More Challenges
- Powered by:
nature jobs
Senior Scientist, Bioinformatics and Protein Design
- Novo Nordisk Foundation Center for Protein Research, University of Copenhagen
- Copenhagen 2200 Denmark
Team Leader for Analytical Development
- Novo Nordisk
- Bagsværd, Denmark
Man on a mission
Meredith Wadman
Abstract
A look at the world of Steven Nissen, the cardiologist who raised worries about Vioxx and Avandia.
It isn't every clinical scientist who in the space of a month sends a major drug company's stock plummeting, is invited to testify at Congress and is crowned one of the world's 100 most influential people by Time magazine. But then, they aren't Steven Nissen, the cardiologist who last week fingered the diabetes drug Avandia as carrying a possible risk of heart attacks (see Weighing up the evidence).
To read this story in full you will need to login or make a payment (see right).
